

Centre for Commercialization of **Regenerative** Medicine

DEVELOPMENT OF AN INTEGRATED BIOPROCESS FOR HIGH-DENSITY CULTURE OF IMMUNOTHERAPEUTIC NK-92 CELLS

BACKGROUND AND MOTIVATION

• NK-92 cells exhibit cytotoxicity against a variety of cancer cell lines, including leukemia's, lymphoma's, and malignant melanoma's. This activity has lead to several small clinical trials as an anti-cancer immunotherapy, with larger multi-centre Phase II trials planned.






Figure 1. The current manufacturing strategy for NK-92 based on static bag culture is expensive and not scalable for large patient numbers. Translation into closed dynamic culture systems will allow for more efficient expansion, lower labour and infrastructure costs, and a clear path for scale-up. Culture intensification combined with more efficient downstream processing are identified as targets for process improvement.

- The current production strategy relies on static culture techniques, resulting in large culture volumes and high cost. Volume and cost are further inflated by inefficient harvest and wash, with cell losses as high as 50%.
- Our *GOAL* is to enable cost-effective large-scale manufacture of clinical grade NK-92 cells.

NK92 TRANSLATION TO STIRRED TANK REACTORS – FED-BATCH FEEDING

NK-92 inoculation (100 mL @ 0.5M cells/mL) cultured for six days, with media doubled every 2nd day. STR resulted in greater cell expansion compared to static culture.







Successful transition of static culture to STR . > Accumulation of lactate may limit cell expansion/potency, rationale for perfusion culture.

BIOSEP CELL CONCENTRATION

• NK-92 cells in suspension (150 mL, 0.5M cells/mL) were concentrated using the Mini BioSep at flow rates up to 1.2 mL/min. High separation efficiency (SE) was observed, with minimal loss of cells in the waste stream. SE (%) = $\left(1 - \frac{\text{VCD harvest}}{\text{VCD bulk}}\right) \cdot 100$



Howard Kim¹, Ricardo P. Baptista¹, Anne D'Umbruoso², Felix Trampler³, Peter W. Zandstra¹ and Nicholas E. Timmins¹ 1. Centre for Commercialization of Regenerative Medicine, Toronto, Canada, 2. Applikon[®] Biotechnology, 3. SonoSep[®] Technologies






Figure 2. The MiniBio stirred tank reactor (STR) system from Applkon with a BioSep acoustic filter unit. STRs provide a closed, dynamically-controlled, and scalable system for cell expansion. The BioSep (right) generates standing acoustic waves to capture cells in suspension, allowing for the removal of spent media. This technology has been extensively demonstrated for perfusion culture but could also be useful for cell harvest, wash, and concentration.

Figure 3. A) NK-92s expand faster in STRs compared to static, but both systems show a decrease in viable cell density (VCD) at day 6. B) Lactate accumulates in cultures and may explain growth inhibition. This effect is higher in STR due to higher cell densities. Glucose was not limiting (data not presented). C) Although the NK phenotype is maintained, cells cultured in STRs loose potency. (n=3)



BIOSEP ACOUSTIC FILTRATION FOR INTEGRATED PERFUSION CULTURE, HARVEST AND WASH

AIMS

OBJECTIVES

- Translate NK-92 expansion protocol into stirred tank reactors.
- Define BioSep parameters for optimal separation efficiency.
- Intensify cultures for higher cell densities through optimized perfusion feeding strategies.
- Demonstrate high efficiency harvest and wash with minimal process time.
- Integrate culture and downstream processes.
- Scale process to produce clinically relevant cell quantities.

STR CULTURES WITH BIOSEP PERFUSION - PRELIMINARY RESULTS





Expand NK-92 cells in stirred-tank bioreactors (STR) with BioSep-based perfusion feeding to enable an intensified culture process that is readily scaled for commercial manufacture. Integrate BioSep separation technology for efficient downstream harvesting and wash.